Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An inherited disorder that affects the metabolism of any acidic compound containing carbon in a covalent linkage.
No HPO annotations are available for this condition.
Age of onset: newborn period.
The phenotypic spectrum of untreated glutaric acidemia type 1 (GA-1) ranges from the more common form (infantile-onset disease) to the less common form (later-onset disease after age 6 years). Of note, the GA-1 phenotype can vary widely among untreated family members with the same genotype, primarily as a function of the age at which the first acute encephalopathic crisis occurred: three months to three years in infantile-onset GA-1 and after age six years in later-onset GA-1 . Characteristically these crises result in acute bilateral striatal injury and subsequent complex movement disorders. Patients may also develop insidious-onset basal ganglia injury in the absence of an identified acute encephalopathic crisis.
Source: GeneReviews — "Glutaric Acidemia Type 1"
Guidelines for diagnosis and management of glutaric acidemia type 1 (GA-1) due to deficiency or absence of functional glutaryl-CoA dehydrogenase were developed in 2007 and recently revised .
Suggestive Findings
GA-1 should be suspected in infants with a positive NBS result. NBS for GA-1 primarily relies on measuring glutarylcarnitine (C5DC) in dried blood spots, which has been shown to have 96% sensitivity . Positive C5DC values (i.e., those above the cutoff reported by the screening laboratory) require follow-up biochemical testing with either urine organic analysis or quantitative glutaric and 3-hydroxyglutaric acid, with preference for quantitative studies if available.
Source: GeneReviews — "Glutaric Acidemia Type 1"
Table 2. Other Genes of Interest in the Differential Diagnosis of Glutaric Acidemia Type 1 (GA-1)
Gene(s) | DiffDx Disorder | MOI | Clinical Features of DiffDx Disorder |
|---|---|---|---|
Significantoverlappingfeatures | Other clinical features | Laboratory/Imaging findings ETFA ETFB | — |
ETFDH | Glutaric acidemia type 2 (See Multiple Acyl-CoA Dehydrogenase Deficiency.) |
Biomarker and diagnostic research for inborn organic aciduria has been reported in the published literature.
No approved treatments are currently available for inborn organic aciduria. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for inborn organic aciduria, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for inborn organic aciduria. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
Carbaglu | carglumic acid | Recordati Rare Diseases | 2014 | 2028 | Designated (drug approved for other indication) |
Gene therapy approaches for inborn organic aciduria have been reported in the published literature.
When glutaric acidemia type 1 (GA-1) is suspected during the diagnostic evaluation (i.e., due to elevated concentration of 3-OH-GA in plasma or urine), metabolic treatment should be initiated immediately. Development and evaluation of treatment plans, training and education of affected individuals and their families, and avoidance of side effects of dietary treatment (i.e., malnutrition, growth failure) require a multidisciplinary approach to care including multiple subspecialists, with oversight and expertise from a specialized metabolic center. The second revision of consensus clinical practice guidelines for the treatment of individuals with GA-1 have recently been published .
To establish the extent of disease and needs in an individual following diagnosis of GA-1, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended.
Table 3.
Recommended Evaluations Following Initial Diagnosis of GA-1
Evaluation | Comment
Consultation w/metabolic physician / biochemical geneticist specialist metabolic dietician1 | • Transfer to specialist center w/experience in management of inherited metabolic diseases is strongly recommended.
Consider short hospitalization at center of expertise for inherited metabolic conditions to provide detailed education (natural history, maintenance emergency treatment, prognosis, risks for acute encephalopathic crises) for caregivers.
Source: GeneReviews — "Glutaric Acidemia Type 1"
Avoid the following:
Excessive dietary protein or protein malnutrition inducing catabolic state
Prolonged fasting
Catabolic illness (intercurrent infection; brief febrile illness post-vaccination)
Inadequate caloric provision during other stressors, especially when fasting is involved (surgery or procedure requiring fasting/anesthesia)
Although there are no data on which to base such a recommendation, given the increased risk of subdural hemorrhage in individuals with GA-1, avoidance or extreme caution with contact sports and physical activities that involve high risk for minor head injuries would appear to be a sensible precaution.
Source: GeneReviews — "Glutaric Acidemia Type 1"
View trials for inborn organic aciduria
Regular evaluations by a metabolic specialist and metabolic dietician are appropriate. See for additional recommended surveillance. Table 9. Recommended Surveillance for Individuals with Glutaric Aciduria Type 1
Manifestation/Concern | Evaluation | Frequency/Comment |
|---|---|---|
Poor growth | Measurement of growth, weight, head circumference | At each visit |
Delayed acquisition of developmental milestones | Monitor developmental milestones. | At each visit Neuropsychological testing using age-appropriate standardized assessment batteries |
Movement disorder | Assessment for clinical symptoms signs of movement disorders, severity, responses to treatment, physical therapy, pharmacologic interventions | At each visit |
Abnormal amino acid levels (amino acid deficiencies lysine) | Quantitative analysis of plasma amino acids (ideally obtained after a 3-hr protein fast)1 | 1st year of life: at least every 3 mos; Ages 1-6 yrs: every 6 mos; 6 yrs of age: annually |
Nutritional deficiencies2 | Calcium, phosphorus, vitamin D, prealbumin, B12, zinc, ferritin | If clinically indicated3 |
Chronic renal insufficiency4 | Plasma creatinine /or cystatin C level | Periodically in adolescents adults |
Anemia | Complete blood count, ferritin level | If clinically indicated3 |
Abnormal liver function | ALT/AST , albumin | If clinically indicated3 |
Head injury5 /or rapid head growth6 | Consider head MRI. | If clinically indicated7 ALT = alanine transaminase; AST = aspartate transaminase 1. Correlations between plasma lysine concentration and dietary lysine intake are often poor . 2. |
Source: GeneReviews — "Glutaric Acidemia Type 1"
No clinical trials have been registered for inborn organic aciduria.
116 publications have been identified in PubMed for inborn organic aciduria. Research spans Case Report / Case Series (28%), Diagnostic / Biomarker (22%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 33 | 28% |
Testing and diagnosis research | 26 | 22% |
Research summaries | 20 | 17% |
Disease patterns and progression | 17 | 15% |
Laboratory research | 14 | 12% |
Other research | 2 | 2% |
Clinical study results | 2 | 2% |
New treatment approaches | 2 | 2% |
Ferrera G (2026). [PMID: 42082260](https://pubmed.ncbi.nlm.nih.gov/42082260/). *BMJ Case Rep*. [Case Report / Case Series]
Gokalp S (2026). [PMID: 42100905](https://pubmed.ncbi.nlm.nih.gov/42100905/). *Clin Dysmorphol*. [Case Report / Case Series]
Baheer Abdulwahhab S (2026). [PMID: 41868448](https://pubmed.ncbi.nlm.nih.gov/41868448/). *Cureus*. [Case Report / Case Series]
Zhou Y (2026). [PMID: 40581590](https://pubmed.ncbi.nlm.nih.gov/40581590/). *Hepatobiliary Pancreat Dis Int*. [Other]
Barbetti R (2026). [PMID: 42181774](https://pubmed.ncbi.nlm.nih.gov/42181774/). *Mol Genet Metab Rep*. [Case Report / Case Series]
Jennings EA (2026). [PMID: 42105943](https://pubmed.ncbi.nlm.nih.gov/42105943/). *Clin Chim Acta*. [Review / Meta-Analysis]
Bandura A (2026). [PMID: 41722717](https://pubmed.ncbi.nlm.nih.gov/41722717/). *Clin Biochem*. [Diagnostic / Biomarker]
Nasri M (2026). [PMID: 41527137](https://pubmed.ncbi.nlm.nih.gov/41527137/). *Orphanet J Rare Dis*. [Diagnostic / Biomarker]
Urquiza N (2026). [PMID: 41475179](https://pubmed.ncbi.nlm.nih.gov/41475179/). *Mol Genet Metab*. [Case Report / Case Series]
Zhang R (2026). [PMID: 41088720](https://pubmed.ncbi.nlm.nih.gov/41088720/). *Dev Med Child Neurol*. [Epidemiology / Natural History]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
glutaric acid |
SUGCT | Glutaric acidemia type 3 (OMIM 231690) | AR | glutaric acid |
Canavan disease | AR | Macrocephaly | Hypotonia; DD regression; Seizures; Optic atrophy |
Leukodystrophy on MRI 60 genes (mt nuclear)1 | Leigh syndrome (See Mitochondrial DNA-Associated Leigh Syndrome and NARP Nuclear Gene-Encoded Leigh Syndrome Overview.) | MatAR(XL) | Metabolic encephalopathy predisposing to basal ganglia disease |
Isolated methylmalonic acidemia | AR | Metabolic encephalopathy predisposing to basal ganglia disease | Decompensation w/illness; DD; Cardiomyopathy; Renal failure; Pancreatitis; Bone marrow suppression; Optic atrophy |
Source: GeneReviews — "Glutaric Acidemia Type 1"